medigraphic.com
ISSN 0210-5187 (Digital)

2007, Número 1

<< Anterior Siguiente >>

Med Cutan Iber Lat Am 2007; 35 (1)


Confrontando al melanoma en el siglo XXI

Gutiérrez VRM, Cortés LN

Idioma: Español
Referencias bibliográficas: 72
Paginas: 3-13
Archivo PDF: 271.66 Kb.


RESUMEN

El melanoma maligno es un tumor derivado de la proliferación de melanocitos atípicos, caracterizado por su gran capacidad de dar metástasis. Su frecuencia ha aumentado hasta en el 400% en las últimas décadas y hoy, como hace 20 años, el diagnóstico precoz y el tratamiento oportuno son las únicas estrategias para mejorar el pronóstico de los pacientes con melanoma. Se presenta una revisión de la literatura, los factores de riesgo asociados, sus criterios diagnósticos, pronóstico y tratamiento.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.Goldstein BG, Goldstein A. Diagnosis and management of malignant melanoma. Am Fam Physician 2001;63:1359-68.

  2. 2.Registro Histopatológico de las Neoplasias Malignas. Compendio de Cáncer. Secretaria de Salud 2001. México.

  3. 3.De Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia. Int J Cancer 2003;107:119-26.

  4. 4.MacKie RM, Bray CA, Hole DJ, Morris A, Nicolson M, Evans A, Doherty V, Vestey J. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002;360:587-91.

  5. 5.Builliard JL. Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int J Cancer 2000;85:627-32.

  6. Garbe C, Büttner P, Bertz J, Burg G, d’Hoedt B, Drepper H y cols. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995;10:2492-8.

  7. 7.Balch CM, Soong SJ, Gershenwald, JE, Thompson JF, Reintgen DS, Cascinelli N y cols. Prognostic factors analysis of 17,600 melanoma patients; validation of the American Joint Commettee on Cancer Melanoma Staging System. J Clin Oncol 2001;19:3622-34.

  8. 8.Streetly A, Markowe H. Changing trends in the epidemiology of malignant melanoma: gender differences and their implications for public health. J Int Epidemiol 1995;24:897-907.

  9. 9.Jemal A, Clegg L, Ward E, Ries LA, Wu X, Jamison PM y cols. Annual Report to the Nation on the status of cancer, 1975-2001, with special feature regarding survival. Cancer 2004;101:3-27.

  10. 10.Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Eng J Med 2004;351:998-1012.

  11. 11.International Agency for Research on Cancer. GLOBOCAN 2002. CANCER Mondial página web: http://www-dep.iarc.fr/

  12. Martínez-Saíd H, Cuéllar-Hubbe M, Barrón-Velasquez E, Padilla RA, Herrera-Gómez A, López-Graniel CM. Epidemiology of cutaneous melanoma in Mexico (1982-2002). Eur J Surg Oncol 2004;30:163.

  13. 13.Jacobo R, Pineda B, León G. Melanoma maligno cutáneo. Perfil epidemiológico en México. Gaceta Mex Oncol Abril-Junio, 2003;2:17-22.

  14. Dennis LK. Analysis of the melanoma epidemic, both apparent and real: Data from the 1973 through 1994 Surveillance, Epidemiology, and End Results program registry. Arch Dermatol 1999;135:275-80.

  15. Van der Rhee HJ, Van der Spek-Keijser LM, Van Westering R, Coebergh JW. Increase in and stabilization of incidence and mortality of primary cutaneous malignant melanoma in western Netherlands, 1980-95. Br J Dermatol 1999;140: 463-7.

  16. Schaffer JV, Rigel DS, Kopf AW, Bolognia JL. Cutaneous melanoma- Past, present and future. J Am Acad Dermatol 2004; 51: S65-9.

  17. 17.Brochez L, Verhaeghe E, Sales F, Del Marmol V, Deraemaecker R, Vossaert K, Naeyaert JM. Current guidelines in melanoma treatment. Melanoma Working Group of Gent and Bordet. Dermatology 2000; 200:160-6.

  18. Brochez L, Naeyaert JM. Understanding the trends in melanoma incidence and mortality: where do we stand? Eur J Dermatol 2000;10:71-6.

  19. 19.Desmond RA, Soong S. Epidemiology of malignant melanoma. Surg Clin North Am 2003; 83:1-29.

  20. CastillaEE,Da Graca DutraM, Orioli-Parreiras IM.Epidemiology of congenital pigmented naevi, I: Incidence rates and relative frequencies. Br J Dermatol 1981;104:307-15.

  21. 21.Ruiz-MaldonadoR,TamayoL,LaterzaAM, Durán C. Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pediatr 1992;120:906-11.

  22. 22.MarghoobAA,SchoenbachSP,KopfAW, Orlow SJ, Nossa R, Bart RS. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study. Arch Dermatol 1996;132:170-5.

  23. SwerdlowAJ,EnglishJS,QiaoZ.The risk of melanoma in patients with congenital nevi: a cohort study. J Am Acad Dermatol 1995;32:595-99.

  24. 24.Tannous ZS, Mihm MC, Sober AJ, Duncan LM. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol 2005;52:197-203.

  25. 25.Clark WH Jr, Reimer RR, Green M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. “The B-K mole syndrome”. Arch Dermatol 1978;114:732-8.

  26. Lynch HT, Frichot BC, Lynch JF. Familial atypical multiple mole melanoma syndrome. J Med Genet 1978;15:352-6.

  27. 27.Consensus developement panel on early melanoma. Diagnosis and treatment of early melanoma. JAMA 1992;268:1314-9.

  28. 28.Swerdlow AJ, English J, MacKie RM. Benign melanocyte nevi as a risk factor for malignant melanoma. Br Med J 1986;292: 1555-9.

  29. 29.ParkerJF, FlorellSR, AlexanderA, DiSario JA, Shami PJ, Leachman SA. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol 2003;139: 1019-1025.

  30. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 2000;42:705-23.

  31. Puig S, Malvehy J, Badenas C, Ruiz A, Jiménez D, Cuéllar F y cols. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 2005;23:3043-51.

  32. 32.Heymann WR. The genetics of melanoma. J Am Acad Dermatol 2004;51:801-2.

  33. Tsao H, Niendorf K. Genetic testing in hereditary melanoma. J Am Acad Dermatol 2004;51:803-8.

  34. TsaoH,GoelV, WuH,Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122:337-41.

  35. 35.DuncanLM, DeedsJ,CroninFE, Donovan M, Sober AJ, Kauffman M, McCarthy JJ. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 2001;19:568-76.

  36. Estadísticas del Servicio de Dermato-oncología del Hospital General de México. México, 2002.

  37. Estadísticas del Servicio de Dermatología del Instituto Nacional de Cancerología. México, 2004.

  38. Estadísticas del Servicio de Dermato-oncología del Centro Dermatológico “Dr. Ladislao de la Pascua”. México, 2002.

  39. 39.Richardson SK, Tannous ZS, Mihm MC. Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment- synthesizing melanoma. J Am Acad Dermatol 2002;47:77-90.

  40. 40.Altman JF, Lowe L, Redman B, Esper P, Schwartz JL, Johnson TM, Haefner HK. Placental metastasis of maternal melanoma. J Am Acad Dermatol 2003;49:1150-4.

  41. Lin D, Kashani-Sabet M, McCalmont T, Singer MI. Neurotropic melanoma invading the inferior alveolar nerve. J Am Acad Dermatol 2005;53(Supl. 1):S120-2.

  42. 42.Liu V, Mihm MC. Pathology of malignant melanoma. Surg Clin North Am 2003;83:31-60.

  43. 43.Tomicic J, Wanebo HJ. Mucosal melanomas. Surg Clin North Am 2003;83:237-52.

  44. 44.McGovern TW, Litaker MS. Clinical predictors of malignant pigmented lesions. A comparison of the Glasgow seven-point checklist and the American Cancer Society’s ABCDs of pigmented lesions. J Dermatol Surg Oncol 1992;18:22-6.

  45. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002;3:159-65.

  46. 46.Grin CM, Kopf AW, Welkovich B, Bart RS, Levenstein MJ. Accuracy in the clinical diagnosis of malignant melanoma. Arch Dermatol 1990;126:763-6.

  47. Argenziano G, Soyer HP. Dermoscopy of pigmented skin lesions: a valuable tool for early diagnosis of melanoma. Lancet Oncol 2001;2:443-9.

  48. 48.Skvara H, Teban L, Fiebiger M, Binder M, Kittler H. Limitations of dermoscopy in the recognition of melanoma. Arch Dermatol 2005;141:155-60.

  49. 49.Pehamberger H, Binder M, Steiner A, Wolff K: In vivo epiluminescence microscopy: improvement of early diagnosis of melanoma. J Invest Dermatol 1993;100:356S-62S.

  50. Binder M, Schwarz M, Winkler A, Steiner A, Kaider A, Wolff K, Pehamberger H. Epiluminescence microscopy: a useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Dermatol 1995;131:286-91.

  51. 51.Binder M, Kittler H, Steiner A, Dawid M, Pehamberger H, Wolff K. Reevaluation of the ABCD rule for epiluminescence microscopy. J Am Acad Dermatol 1999;40:171-6.

  52. Binder M, Puespoeck-Schwarz M, Steiner A, Kittler H, Muellner M, Wolff K, Pehamberger H. Epiluminescence microscopy of small pigmented skin lesions: short-term formal training improves the diagnostic performance of dermatologists. J Am Acad Dermatol 1997;36:197-202.

  53. Stolz W, Riemann A, Cognetta AB, Pillet L, Abmayr W, Hölzel D, Bilek P, Nachbar F y cols.: The ABCD rule of dermoscopy: a new practical method for early recognition of malignant melanoma. Eur J Dermatol 1994;7:521-8.

  54. Argenziano G, Fabbrocini G, Carli P, De Giorgi V, Sammarco E, Delfino M. Epilumines- cence microscopy for the diagnosis of doubtful melanocytic skin lesions: comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol 1998;134:1563-70.

  55. Bafounta ML, Beauchet A, Aegerter P, Saiag P.Is dermoscopy (epiluminescence micros- copy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol 2001;137:1343-50.

  56. Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol 2000;43:467-76.

  57. 57.Marghoob AA, Swindle L, Moricz CZ, Sanchez Negron FA, Slue B, Halpern AC, Kopf AW. Instruments and new technologies for the in vivo diagnosis of melanoma. J Am Acad Dermatol 2003;49:777-97.

  58. Elbaum M. Computer-aided melanoma diagnosis. Dermatol Clin 2002;20:735-47.

  59. 59.Moncrieff M, Cotton S, Claridge E, Hall P. Spectrophotometric intracutaneous analysis: a new technique for imaging pigmented skin lesions. Br J Dermatol 2002;146:1-11.

  60. 60.Swanson NA, Lee KK, Gorman A, Han H. Biopsy techniques. Diagnosis of melanoma. Dermatol Clin 2002;20:677-80.

  61. Brady MS. Sentinel lymph node mapping in patients with cutaneous melanoma. Dermatol Surg 2004;30:272-8.

  62. 62.Saiag P, Bernard M, Beauchet A, Bafounta ML, Bourgault-Villada I, Chagnon S. Ultrasonography using simple diagnostic criteria vs palpation for the detection of regional lymph node metastases of melanoma. Arch Dermatol 2005;141:183-9.

  63. 63.Dubois RW, Swetter SM, Atkins M, McMasters K, Halbert R, Miller SJ y cols.: Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alpha-2b in melanoma. Arch Dermatol 2001;137:1217-24.

  64. Padilla-Longoria R, Alfeirán-Ruiz A, León E, Barra-Martínez R, Beltrán-Ortega A, Padilla-Rosciano AH y cols.: Manejo de los relevos linfáticos y determinación del ganglio centinela en melanoma. Primer Consenso Nacional de Expertos en Melanoma. Gaceta Mexicana de Oncología 2005;4(Supl. 2):20-3.

  65. 65.Reeves ME, Delgado R, Busam KJ, Brady MS, Coit DG. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 2003;10:27-31.

  66. Wolf IH, Richtig E, Kopera D, Kerl H. Locoregional cutaneous metastases of malignant melanoma and their management. Dermatol Surg 2004;30:244-7.

  67. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG y cols.: Final version of the American Joint Commettee on Cancer Staging System for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.

  68. 68.McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma. Cancer 2003; 98:1223-31.

  69. 69.Slingluff CL, Vollmer RT, Reintgen DS, Seigler HF. Lethal “thin” malignant melanoma: identifying patients at risk. Ann Surg 1988; 208:150-61.

  70. 70.Wang X, Heller R, VanVoorhis N, Cruse CW, Glass F, Fenske N y cols.: Detection of submicroscopic lymph node metastasis with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220: 768-74.

  71. Vega-González MT, Toussaint-Caire S, Gutiérrez-Vidrio RM, Orozco-Topete RL, León E, Martínez-Saíd H y cols.: Manejo de las lesiones pigmentadas. Primer Consenso Nacional de Expertos en Melanoma. Gaceta Mexicana de Oncología 2005;4(Supl. 2):14-7.

  72. Sober AJ, Fitzpatrick TB, Mihm MC. Primary melanoma of the skin: recognition and management. J Am Acad Dermatol 1980; 2:179-97.




2020     |     www.medigraphic.com